Peregrine initiates dosing in Phase II lung cancer trial
Peregrine Pharmaceuticals has initiated patient screening and dosing in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer.
This entry was posted on Wednesday, July 2nd, 2008 at 9:52 am and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.